The Columbus Community Clinical Oncology Program has been a successful CCOP since its original designation in 1983. The Columbus CCOP was created to support the participation of community physicians in clinical research, both by accrual, protocol design and reporting. This gives our patients access to state-of-the-art cancer therapies. Our work has expanded during these 12 years to include participation in cancer control research, particularly cancer screening and prevention, as well as recruitment of primary care physicians and non-oncologists to achieve that end. New strategies have been designed to enroll patients and healthy subjects into cancer treatment and control protocols, and to review and submit data in an efficient, timely, and accurate manner. We view education of physicians, allied health professionals and the public as a major priority, and anticipate that these efforts will increase as the prevention and treatment of cancer becomes a major goal of all participants and payors in future health care delivery systems. One of the 62 original CCOPs, the Columbus CCOP continues to demonstrate a strong commitment and ability to fulfill the goals of the original program description. Despite several changes in internal government, personnel and participating hospitals, the institution has shown its ability to continue to accrue patients and provide high quality data in a timely fashion to its three research bases, SWOG, NSABP, and MD Anderson. Our member hospitals have each contributed $50,000 to $150,000 annually, and support our activities in many ways. Our experienced principal investigators and associates, our key personnel and our physician members are enthusiastic, eager to continue our successful collaboration with the NCI as we approach the Year 2000.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA035261-12
Application #
2088895
Study Section
Special Emphasis Panel (SRC (16))
Project Start
1983-09-30
Project End
2000-05-31
Budget Start
1995-07-03
Budget End
1996-05-31
Support Year
12
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Columbus Community Clinical Oncology Prg
Department
Type
DUNS #
City
Columbus
State
OH
Country
United States
Zip Code
43215
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32

Showing the most recent 10 out of 151 publications